Aptevo Therapeutics, Inc. (APVO) - Cash on Hand per Share

Aptevo Therapeutics develops immuno-oncology drugs using its unique, patent-protected ADAPTIR platform. The change in cash per share demonstrates current liquidity, with the indicator standing at 2.39. However, capital deficits and uncertainty surrounding clinical trials create financial risks. Growth potential is driven by the expansion of its global network of research centers within the bispecific antibodies segment.
Analytical breakdowns for Aptevo Therapeutics, Inc. (APVO)

The fundamental value of Aptevo Therapeutics (APVO) requires a rigorous liquidity analysis to assess investment risks. The calculated cash per share determines the portion of free cash available for each security. This metric serves as an indicator of financial stability and protection against default. For Aptevo Therapeutics, this figure is critical due to the shortage of funds for the development of the ADAPTIR platform. Constant liquidity monitoring allows for an assessment of the company's ability to finance long-term antibody research.